Development and evaluation of a patient-reported outcome measure specific for Gaucher disease with or without neurological symptoms in Japan

被引:1
|
作者
Narita, Aya [1 ]
Koto, Yuta [2 ]
Noto, Shinichi [3 ]
Okada, Masafumi [4 ]
Ono, Midori [5 ]
Baba, Terumi [5 ]
Sagara, Rieko [5 ]
Sakai, Norio [6 ]
机构
[1] Tottori Univ, Div Child Neurol, Inst Neurol Sci, Fac Med, Yonago, Japan
[2] Osaka Aoyama Univ, Fac Hlth Sci, Sch Nursing, Osaka, Japan
[3] Niigata Univ Hlth & Welf, Dept Rehabil, Niigata, Japan
[4] IQVIA Solut Japan KK, Real World Evidence Solut & HEOR, Tokyo, Japan
[5] Takeda Pharmaceut Co Ltd, Japan Med Off, Tokyo, Japan
[6] Osaka Univ, Grad Sch Med, Div Hlth Sci, Child Healthcare & Genet Sci Lab, 1-7 Yamadaoka, Suita, Osaka 5650871, Japan
关键词
Gaucher disease; Japan; Patient reported outcome measures; Quality of life; Burden of disease; Neuronopathic Gaucher disease; Reliability; Validity;
D O I
10.1186/s13023-023-02996-9
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background Patients with Gaucher disease (GD), a rare lysosomal storage disorder, have reduced health-related quality of life (HRQOL). A patient-reported outcome measure (PROM) for HRQOL developed for type 1 GD (GD1) is not appropriate for patients with neuronopathic GD (nGD) types 2 (GD2) and 3 (GD3). In this study, we developed a new PROM for use in all GD types. We previously reported the qualitative analysis of interviews with Japanese patients with nGD, which was used to create nGD-specific PROM items. Here we evaluated the full PROM combining the type 1 questionnaire with the new nGD-specific items.Methods Patients with confirmed GD were recruited (Association of Gaucher Disease Patients in Japan or leading doctors) for pre-testing (May 2021) or the main survey (October-December 2021). The PROM had three parts: Parts 1 and 2 were translated into Japanese from the pre-existing GD1 PROM, whereas Part 3 was newly developed. Patients (or their caregivers, where necessary) completed the PROM questionnaire on paper and returned it by mail. Mean scores were determined overall and by GD type. Inter-item correlations, content consistency (Cronbach's alpha), and test-retest reliability (Cohen's kappa; main survey only, taken 2 weeks apart) were calculated.Results Sixteen patients (three with GD1; six with GD2; seven with GD3) and 33 patients (nine with GD1; 13 with GD2; 11 with GD3) participated in the pre-test and main survey, respectively. All GD2 patients and one-third (6/18) of GD3 patients required caregivers to complete the questionnaire. Mean scores indicated that the burden was highest in GD2 and lowest in GD1. In the main survey, internal consistency was high (Cronbach's alpha = 0.898 overall, 0.916 for Part 3), and test-retest reliability was high for Part 3 (kappa > 0.60 for 13/16 items) but low for Part 1 (kappa < 0.60 for 12/15 items).Conclusions We have developed a flexible and reliable PROM that can be tailored for use in all types of GD and propose using Parts 1 and 2 for GD1, Parts 2 and 3 for GD2, and Parts 1, 2, and 3 for GD3.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Pediatric Simple Knee Value: a simple patient-reported outcome measure for the knee
    Marot, Vincent
    Vilette, Hugo
    Dalmas, Yoann
    Justo, Arthur
    Reina, Nicolas
    Cavaignac, Etienne
    Berard, Emilie
    Accadbled, Franck
    JOURNAL OF CHILDRENS ORTHOPAEDICS, 2021, 15 (01) : 76 - 80
  • [22] Validation of a patient-reported outcome measure for giant cell arteritis
    Ndosi, Mwidimi
    Almeida, Celia
    Dawson, Jill
    Dures, Emma
    Greenwood, Rosemary
    Bromhead, Alison
    Guly, Catherine
    Stern, Steve
    Hill, Catherine
    Mackie, Sarah
    Robson, Joanna C.
    RHEUMATOLOGY, 2024, 63 (01) : 181 - 189
  • [23] Development of a condition-specific patient-reported outcome measure for measuring symptoms and appearance in vascular malformations: the OVAMA questionnaire
    Lokhorst, M. M.
    Horbach, S. E. R.
    Young-Afat, D. A.
    Stor, M. L. E.
    Haverman, L.
    Spuls, P. I.
    van der Horst, C. M. A. M.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (04) : 797 - 803
  • [24] Evaluation of the effect of urethroplasty for anterior urethral strictures by a validated disease-specific patient-reported outcome measure
    Akio Horiguchi
    Masayuki Shinchi
    Kenichiro Ojima
    Ayako Masunaga
    Keiichi Ito
    Tomohiko Asano
    Eiji Takahashi
    Fumihiro Kimura
    Ryuichi Azuma
    World Journal of Urology, 2019, 37 : 601 - 606
  • [25] Measurement properties of a patient-reported outcome measure assessing psoriasis severity: The psoriasis symptoms and signs diary
    Mathias, Susan D.
    Feldman, Steven R.
    Crosby, Ross D.
    Colwell, Hilary H.
    McQuarrie, Kelly
    Han, Chenglong
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2016, 27 (04) : 322 - 327
  • [26] Evaluation of the effect of urethroplasty for anterior urethral strictures by a validated disease-specific patient-reported outcome measure
    Horiguchi, Akio
    Shinchi, Masayuki
    Ojima, Kenichiro
    Masunaga, Ayako
    Ito, Keiichi
    Asano, Tomohiko
    Takahashi, Eiji
    Kimura, Fumihiro
    Azuma, Ryuichi
    WORLD JOURNAL OF UROLOGY, 2019, 37 (04) : 601 - 606
  • [27] Development of a Patient-Reported Outcome Measure for Children With Streptococcal Pharyngitis
    Shaikh, Nader
    Martin, Judith M.
    Casey, Janet R.
    Pichichero, Michael E.
    Wald, Ellen R.
    Colborn, Kathleen
    Gerber, Michael A.
    Kearney, Diana H.
    Balentine, Tracy L.
    Haralam, Mary Ann
    Hoberman, Alejandro
    PEDIATRICS, 2009, 124 (04) : E557 - E563
  • [28] Development and Validation of a Patient-Reported Outcome Measure for Fingernail and Toenail Conditions: The NAIL-Q
    Klassen, Anne F.
    Rae, Charlene
    O'Malley, Maureen
    Breitkopf, Trisia
    Algu, Leah
    Mansouri, Jasmine
    Brown, Claire R.
    Wang, Yi
    Lipner, Shari R.
    CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2023, 16 : 3091 - 3105
  • [29] Development of a patient-reported outcome measure in limb reconstruction A PILOT STUDY ASSESSING FACE VALIDITY
    Wright, J.
    Timms, A.
    Fugazzotto, S.
    Goodier, D.
    Calder, P.
    BONE & JOINT OPEN, 2021, 2 (09): : 705 - 709
  • [30] Development and validation of Gaucher disease type 1 (GD1)-specific patient-reported outcome measures (PROMs) for clinical monitoring and for clinical trials
    Elstein, Deborahy
    Belmatoug, Nadia
    Deegan, Patrick
    Goker-Alpan, Ozlem
    Hughes, Derralynn A.
    Schwartz, Ida Vanessa D.
    Weinreb, Neal
    Bonner, Nicola
    Panter, Charlotte
    Fountain, Donna
    Lenny, Andrew
    Longworth, Louise
    Miller, Rachael
    Shah, Koonal
    Schenk, Jorn
    Sen, Rohini
    Zimran, Ari
    ORPHANET JOURNAL OF RARE DISEASES, 2022, 17 (01)